摘要
目的：观察0.004%曲伏前列素滴眼液（苏为坦）治疗难治性青光眼的有效性及安全性.方法：难治性青光眼患者28例（28眼）,予苏为坦滴眼液点眼,每晚1次.测量用药后1周、4周、12周、24周眼压,与基线眼压进行比较分析,并观察眼部症状体征、视野、血压、脉搏及用药依从性.结果：苏为坦连续点眼1周、4周、12周、24周,眼压下降分别为（7.43±4.17）mmHg,（6.97±4.36）mmHg,（7.82±3.87）mmHg,（7.07±3.91）mmHg,不同时间点眼压下降幅度比较无统计学差异,用药前后视力、视野、视盘C/D值无明显变化,结膜充血见于23眼（82.14%）,用药后出现眼部瘙痒感及刺痛感各一眼（3.57%）,均未影响继续用药,未见全身不良反应.结论：苏为坦治疗难治性青光眼降眼压效果确实、副作用小、患者使用依从性好.
Objective ：To evaluate the effect and safety of Travoprost in treating patients with refractory glaucoma. Methods： 28 eyes of 28 patients with refractory glaucoma were treated with travoprost eyedrops （0.04g/L） as a single therapy once daily. Ontraocular pressure （IOP） at 1, 4, 12 and 24 weeks after sustained instilling were compared with the baseline. And other observed signs included visual acuity, visual field, systematic and local adverse effects. Results.. At 1, 4, 12 and 24weeks after treating, the range of reduction in IOP were （7.43±4.17）mmHg,（6.97±4.36） mmHg, （7.82 ± 3.87）mmHg, （7.07±3.91） mmHg respectively. The visual field, visual field and cup-disc ratio did not change much before and after the medicine was administered. The major adverse effect Was conjunctival congestion which did not affect continuous medication. Conclusion ..Travoprost eyedrops （0.04g/L） reduced IOP significantly as a single therapy in refractory glaucoma. It is effective, safe and well tolerated.
